ArticleJournal of clinical immunology2012

Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

Scott Wilkie et al.PubMed ↗Publisher ↗

No numbers read from the abstract.